As I mentioned, there will be no progress in Q3. They will create ambiguity with their statements to make investors feel like they may directly announce MHRA approvals….this way, investors are not too pissed off the rest of the year for their lack of action thinking we may get MHRA approval PR directly.
Ultimately, it wont be surprising if we find out in the first half of next year that the MAA submission just got accepted….
We are going under 50 cents again or likely under 40 cents in Q3/Q4.
The comment made was more informative as we grasp for any information. The lack of any real PR to the market when it should be put out like the data not embargoed at ASCO presentation information would have been worthwhile to put on the wires. That would’ve gotten more attention than Les on the BBS.
Dark comedy is a very true statement. I am baffled by some actions over the years. Especially from Woodford when they actually needed a larger partner to not having the Journal ready or lack of PR with TLD. Always painted into a corner. Not the management, the retail shareholders always led to believe of actions to happen having to accept this performance.
I always think they will finally execute and it is always “We are working very hard.” I know the assets are worth more but it has been a very dark comedy.
I am confident of approval and production capability but what a wringer we have been put through.